This HTML5 document contains 62 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dcthttp://purl.org/dc/terms/
yago-reshttp://yago-knowledge.org/resource/
dbohttp://dbpedia.org/ontology/
foafhttp://xmlns.com/foaf/0.1/
n12https://global.dbpedia.org/id/
schemahttp://schema.org/
dbthttp://dbpedia.org/resource/Template:
rdfshttp://www.w3.org/2000/01/rdf-schema#
n7http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#
n19http://
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
wikipedia-enhttp://en.wikipedia.org/wiki/
dbphttp://dbpedia.org/property/
provhttp://www.w3.org/ns/prov#
dbchttp://dbpedia.org/resource/Category:
xsdhhttp://www.w3.org/2001/XMLSchema#
wikidatahttp://www.wikidata.org/entity/
goldhttp://purl.org/linguistics/gold/
dbrhttp://dbpedia.org/resource/

Statements

Subject Item
dbr:Scioderm
rdf:type
wikidata:Q24229398 n7:SocialPerson n7:Agent dbo:Agent schema:Organization owl:Thing wikidata:Q4830453 wikidata:Q43229 dbo:Organisation dbo:Company
rdfs:label
Scioderm
rdfs:comment
Scioderm, acquired by Amicus Therapeutics in 2015, was a rare disease company focused on developing a treatment for Epidermolysis Bullosa (EB), a rare genetic disease characterized by extremely fragile skin and recurrent blister formation. There are currently no approved therapies for EB. Scioderm was developing a topical treatment known as SD-101, or Zorblisa, aimed at triggering wound reduction and closure, and a reduction in body surface area coverage of blisters and lesions.
foaf:name
Scioderm
foaf:homepage
n19:sderm.com
dbp:name
Scioderm
dct:subject
dbc:Pharmaceutical_companies_of_the_United_States dbc:Breakthrough_therapy dbc:Orphan_drug_companies dbc:Technology_companies_established_in_2012 dbc:Drug_discovery_companies
dbo:wikiPageID
47655347
dbo:wikiPageRevisionID
965023954
dbo:wikiPageWikiLink
dbr:Breakthrough_Therapy dbr:DEBRA dbr:Orphan_Drug dbr:Amicus_Therapeutics dbc:Breakthrough_therapy dbr:Pharmaceutical_industry dbr:European_Medicines_Agency dbc:Pharmaceutical_companies_of_the_United_States dbr:Epidermolysis_Bullosa dbr:University_of_Minnesota dbc:Orphan_drug_companies dbr:Breakthrough_therapy dbr:Morgenthaler dbr:Food_and_Drug_Administration dbc:Technology_companies_established_in_2012 dbc:Drug_discovery_companies dbr:Connective_tissue_disorder dbr:Durham,_North_Carolina
owl:sameAs
yago-res:Scioderm n12:26GFn wikidata:Q22080551
dbp:wikiPageUsesTemplate
dbt:Infobox_company dbt:COI dbt:Use_dmy_dates dbt:Official_website dbt:Start_date dbt:Reflist
dbp:brands
Zorblisa
dbp:founders
Robert Ryan, Ph.D. Robert Coull, CA, CBV
dbp:hqLocationCity
dbr:Durham,_North_Carolina
dbp:industry
dbr:Pharmaceutical_industry
dbp:products
SD-101 for epidermolysis bullosa
dbo:abstract
Scioderm, acquired by Amicus Therapeutics in 2015, was a rare disease company focused on developing a treatment for Epidermolysis Bullosa (EB), a rare genetic disease characterized by extremely fragile skin and recurrent blister formation. There are currently no approved therapies for EB. Scioderm was developing a topical treatment known as SD-101, or Zorblisa, aimed at triggering wound reduction and closure, and a reduction in body surface area coverage of blisters and lesions. Epidermolysis Bullosa, sometimes referred to as "Butterfly Skin", is a rare genetic connective tissue disorder that, in all forms, results in extremely fragile skin that blisters or tears at the slightest friction or trauma. EB typically manifests at birth or early childhood. According to the Dystrophic Epidermolysis Bullosa Research Association of America (DEBRA), an estimated 1 out of every 20,000 live births are affected with some type of EB and the disorder occurs in every racial and ethnic group throughout the world and affects both sexes equally. In Scioderm's initial open-label Phase 2 study conducted in children with either Simplex, Recessive Dystrophic (RDEB), or Junctional EB, the application of SD-101 resulted in complete closure of 88% of target chronic lesions within one month, in addition to a 57% reduction in Body Surface Area (BSA) coverage of lesions and erosions after 3 months of daily treatment. SD-101, now owned by Amicus Therapeutics, is currently in Phase 3 clinical development to evaluate Zorblisa as a therapy for the treatment of lesions and blistering associated with Epidermolysis Bullosa. Zorblisa is the first drug to ever enter Phase 3 development for the treatment of EB. Stem cell research for Epidermolysis Bullosa is also underway by researchers at the University of Minnesota pursuant to an open-label Phase 2 trial. In April 2013 Scioderm received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its topical treatment, SD-101 for Epidermolysis Bullosa. As a result of receiving Breakthrough therapy designation for SD-101, Scioderm was named a 2013 "Fierce Top 15" company by FierceBiotech. Prior to Scioderm's receipt of the FDA's Breakthrough therapy designation for SD-101, it had only been given to high-profile pharmaceutical companies such as Johnson & Johnson, Merck and Novartis. In addition to Breakthrough therapy designation, Scioderm received Orphan Drug Designation from both the FDA and from the European Medicines Agency (EMA) for its EB treatment.
gold:hypernym
dbr:Company
prov:wasDerivedFrom
wikipedia-en:Scioderm?oldid=965023954&ns=0
dbo:wikiPageLength
9206
dbo:industry
dbr:Pharmaceutical_industry
dbo:locationCity
dbr:Durham,_North_Carolina
foaf:isPrimaryTopicOf
wikipedia-en:Scioderm